Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer
NCT00002937
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of paclitaxel with or without PSC 833 in treating patients with metastatic breast cancer.
Gender:
ALL
Ages:
All
Trial Updated:
01/04/2010
Locations: Beckman Research Institute, City of Hope, Duarte, California +3 locations
Conditions: Breast Cancer
Register for Updates
Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus
NCT00066716
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. Celecoxib may also stop the growth of tumor cells by stopping blood flow to the tumor and/or may block the enzymes necessary for their growth. Combining celecoxib with paclitaxel and carboplatin before surgery may shrink the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/07/2009
Locations: New York Weill Cornell Cancer Center at Cornell University, New York, New York
Conditions: Esophageal Cancer
Register for Updates
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer
NCT00146549
Completed
The purpose of this study is to compare two different combinations of chemotherapy with trastuzumab as initial treatment for HER2 positive advanced breast cancer. Half of the patients will receive trastuzumab in combination with a taxane form of chemotherapy (either paclitaxel or docetaxel), while the other group will receive trastuzumab in combination with vinorelbine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2009
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, Stage IV Breast Cancer
Register for Updates
Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
NCT00313768
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2009
Locations: Pfizer Investigational Site, Bessemer, Alabama +28 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
NCT00625573
Completed
This is an open-label, phase II study to evaluate the efficacy and safety of Abraxane in combination with Capecitabine in patients with metastatic colorectal cancer in the second or third line
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
09/17/2009
Locations: Mount Sinai Medical Center, Miami Beach, Florida
Conditions: Colorectal Cancer
Register for Updates
Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
NCT00002679
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose sequential chemotherapy as adjuvant therapy in treating patients with stage II or stage III breast cancer who have four or more positive axillary lymph nodes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/24/2009
Locations: Yale Comprehensive Cancer Center, New Haven, Connecticut
Conditions: Breast Cancer
Register for Updates
Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00004924
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel together with irinotecan works in treating patients with advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2009
Locations: Yale Comprehensive Cancer Center, New Haven, Connecticut +1 locations
Conditions: Lung Cancer
Register for Updates
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
NCT00251095
Terminated
The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection) administered every week to patients with metastatic breast cancer. The study hypothesis is that the objective response rate with TOCOSOL Paclitaxel given every week is non-inferior to that observed with Taxol given every week.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2009
Locations: Alta Bates Comprehensive Cancer Center, Berkeley, California +13 locations
Conditions: Breast Neoplasm
Register for Updates
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
NCT00077688
Completed
Phase 2B, multicenter study evaluating the safety and efficacy of weekly TOCOSOL Paclitaxel in taxane-naive patients receiving second line chemotherapy for metastatic or locally advanced, unresectable transitional cell carcinoma of the urothelium
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2009
Locations: University of Maryland Medical Center/Greenbaum Cancer Center, Baltimore, Maryland +2 locations
Conditions: Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Carcinoma, Transitional Cell
Register for Updates
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
NCT00087802
Completed
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2009
Locations: Birmingham Hematology and Oncology Associates, LLC, Birmingham, Alabama +69 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy
NCT00004865
Completed
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cetuximab plus cisplatin in treating patients who have metastatic or recurrent cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2009
Locations: Cooper Cancer Institute, Camden, New Jersey +2 locations
Conditions: Head and Neck Cancer
Register for Updates
DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer
NCT00024375
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2009
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland +8 locations
Conditions: Pancreatic Cancer
Register for Updates